60 Degrees Pharmaceuticals (SXTP) Competitors $1.47 +0.02 (+1.38%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.47 0.00 (-0.27%) As of 10/24/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock SXTP vs. PMN, THAR, SNYR, AYTU, RLYB, IBIO, PRPH, ALLR, CASI, and TRAWShould you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Promis Neurosciences (PMN), Tharimmune (THAR), Synergy CHC (SNYR), Aytu BioPharma (AYTU), Rallybio (RLYB), iBio (IBIO), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), CASI Pharmaceuticals (CASI), and Traws Pharma (TRAW). These companies are all part of the "pharmaceutical products" industry. 60 Degrees Pharmaceuticals vs. Its Competitors Promis Neurosciences Tharimmune Synergy CHC Aytu BioPharma Rallybio iBio ProPhase Labs Allarity Therapeutics CASI Pharmaceuticals Traws Pharma Promis Neurosciences (NASDAQ:PMN) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership. Which has higher valuation and earnings, PMN or SXTP? Promis Neurosciences has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals. Promis Neurosciences is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPromis NeurosciencesN/AN/A$2.78M-$0.21-2.0560 Degrees Pharmaceuticals$300K20.09-$7.95M-$50.41-0.03 Do analysts rate PMN or SXTP? Promis Neurosciences presently has a consensus price target of $4.33, indicating a potential upside of 904.25%. 60 Degrees Pharmaceuticals has a consensus price target of $3.00, indicating a potential upside of 104.08%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Promis Neurosciences is more favorable than 60 Degrees Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Promis Neurosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.5060 Degrees Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is PMN or SXTP more profitable? Promis Neurosciences has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -976.86%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Promis NeurosciencesN/A -266.69% -131.59% 60 Degrees Pharmaceuticals -976.86%N/A -133.88% Which has more risk & volatility, PMN or SXTP? Promis Neurosciences has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.79, indicating that its share price is 179% more volatile than the S&P 500. Do insiders and institutionals have more ownership in PMN or SXTP? 50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 3.8% of Promis Neurosciences shares are held by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor PMN or SXTP? In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for 60 Degrees Pharmaceuticals and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.95 beat 60 Degrees Pharmaceuticals' score of 0.63 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPromis Neurosciences beats 60 Degrees Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTP vs. The Competition Export to ExcelMetric60 Degrees PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.03M$2.63B$6.22B$10.81BDividend YieldN/A57.77%5.72%4.81%P/E Ratio-0.0327.9431.5030.91Price / Sales20.09786.96594.92133.93Price / CashN/A168.8137.2561.86Price / Book-0.235.6512.056.61Net Income-$7.95M$33.06M$3.34B$277.10M7 Day Performance-1.34%3.16%1.93%2.57%1 Month Performance5.76%8.14%7.77%3.79%1 Year Performance-63.79%-2.49%56.40%33.01% 60 Degrees Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTP60 Degrees Pharmaceuticals1.9507 of 5 stars$1.47+1.4%$3.00+104.1%-65.7%$6.03M$300K-0.033News CoverageAnalyst ForecastGap UpPMNPromis Neurosciences3.6596 of 5 stars$0.44-2.1%$4.33+884.2%-54.8%$24.21MN/A-2.105Analyst ForecastShort Interest ↓THARTharimmune1.9438 of 5 stars$2.99-5.4%$17.00+468.6%+54.5%$24.04MN/A-0.492Analyst ForecastGap UpSNYRSynergy CHC4.2647 of 5 stars$2.53flat$10.00+295.3%-72.7%$23.84M$34.83M6.6640News CoverageAnalyst DowngradeShort Interest ↓AYTUAytu BioPharma3.5554 of 5 stars$2.36-0.8%$9.17+288.4%+5.6%$23.59M$66.38M-0.84160RLYBRallybio3.2812 of 5 stars$0.56+1.5%$5.00+792.9%-38.6%$23.06M$640K-0.6040Analyst ForecastGap UpIBIOiBio2.892 of 5 stars$1.11+24.3%$4.00+260.4%-56.6%$22.48M$400K-0.64100News CoverageAnalyst ForecastHigh Trading VolumePRPHProPhase Labs0.4953 of 5 stars$0.51-3.4%N/A-83.3%$21.98M$6.77M-0.41130News CoverageAnalyst ForecastGap UpALLRAllarity Therapeutics2.7054 of 5 stars$1.48-2.0%$9.25+525.0%-4.8%$21.93MN/A0.0010News CoverageAnalyst ForecastCASICASI Pharmaceuticals3.9683 of 5 stars$1.71-3.9%$4.00+133.9%-72.1%$21.89M$28.54M-0.59180News CoverageTRAWTraws Pharma0.9075 of 5 stars$2.98-2.9%N/A-46.4%$21.88M$230K0.0317Positive News Related Companies and Tools Related Companies PMN Competitors THAR Competitors SNYR Competitors AYTU Competitors RLYB Competitors IBIO Competitors PRPH Competitors ALLR Competitors CASI Competitors TRAW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SXTP) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
